The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...

People with lupus are at an increased risk of depression. Lupus is a chronic condition with recurring symptoms that can ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...